Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Engelman JA, Shaw AT.

N Engl J Med. 2013 Sep 19;369(12):1173. doi: 10.1056/NEJMc1309091. No abstract available.

2.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Gerlinger M, Norton L, Swanton C.

N Engl J Med. 2013 Sep 19;369(12):1172-3. doi: 10.1056/NEJMc1309091#SA1. No abstract available.

PMID:
24047073
3.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.

N Engl J Med. 2013 Jun 20;368(25):2395-401. doi: 10.1056/NEJMoa1215530.

4.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O.

J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302.

PMID:
25667280
5.

[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].

Svaton M, Pešek M.

Klin Onkol. 2016;29(1):63-5. Czech.

PMID:
26879065
6.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Arnaoutakis K.

N Engl J Med. 2015 Feb 12;372(7):683. doi: 10.1056/NEJMc1415359#SA1. No abstract available.

PMID:
25671265
7.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Solomon BJ.

N Engl J Med. 2015 Feb 12;372(7):683-4. doi: 10.1056/NEJMc1415359. No abstract available.

8.

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G.

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37. No abstract available.

9.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB.

Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. No abstract available.

10.

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.

Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS.

Clin Cancer Res. 2015 May 15;21(10):2379-87. doi: 10.1158/1078-0432.CCR-14-1350.

11.

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lu S, Azada MC, Ou SH.

Lung Cancer. 2015 Feb;87(2):207-9. doi: 10.1016/j.lungcan.2014.12.011.

PMID:
25558789
12.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.

Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J.

Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018.

PMID:
23558310
13.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. No abstract available.

PMID:
25087901
14.

ROS1--targeting the one percent in lung cancer.

Gold KA.

N Engl J Med. 2014 Nov 20;371(21):2030-1. doi: 10.1056/NEJMe1411319. No abstract available.

PMID:
25409376
15.

Lung cancer: alternative rearrangements--targeting ROS1 in NSCLC.

Killock D.

Nat Rev Clin Oncol. 2014 Nov;11(11):624. doi: 10.1038/nrclinonc.2014.180. No abstract available.

PMID:
25311353
16.

Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.

Solomon B.

J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334. No abstract available.

PMID:
25667277
17.

Mouse model for ROS1-rearranged lung cancer.

Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T.

PLoS One. 2013;8(2):e56010. doi: 10.1371/journal.pone.0056010.

18.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

Benderra MA, Aspeslagh S, Postel-Vinay S, Bigot L, De Baere T, Loriot Y, Lacroix L, Massard C, Vassal G, André F, Soria JC.

J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. No abstract available.

PMID:
26845121
19.

More on crizotinib.

Chihara D, Suzuki R.

N Engl J Med. 2011 Feb 24;364(8):776-7; author reply 778. doi: 10.1056/NEJMc1013325#SA1. No abstract available.

PMID:
21345113
20.

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.

Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385.

Items per page

Supplemental Content

Support Center